Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis.

BMC musculoskeletal disorders - 16 Jul 2024

Chen Ding-Qiang, Xu Wen-Bin, Xiao Ke-Yi, Que Zhi-Qiang, Feng Jin-Yi, Sun Nai-Kun, Cai Di-Xin, Rui Gang

Abstract excerpt

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent an effective strategy for reducing cardiovascular disease risk. Yet, PCSK9's impact on osteoporosis remains unclear. Hence, we employed Mendelian randomization (MR) analysis for examining PCSK9 inhibitor effects on osteoporosis. METHODS: Single nucleotide polymorphisms (SNPs) for 3-hydroxy-3-methylglutaryl cofactor A reductase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Associations and Epidemiology
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl CoA Reductases

Share to Lipoproteins and Cardiovascular Health

Share to Mendelian Randomization Analysis

Share to Osteoporosis

Share to Polymorphism, Single Nucleotide

Share to Proprotein Convertase 9

Source

Open in PubMed Open full text

Identifiers

PMID: 39010016
DOI: 10.1186/s12891-024-07674-w
PMCID: PMC11251371

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis.PMID 39010016Read ↗

Impact of PCSK9 inhibitors on bone disease: A comprehensive drug-target Mendelian randomization studySemantic proximity Read ↗

The Causal Relationship between PCSK9 Inhibitors and Osteoporosis Based on Drug-Targeted Mendelian Combined Mediation AnalysisSemantic proximity Read ↗

PCSK9 inhibitors ameliorate arterial stiffness in ACS patients: evidences from mendelian randomization, cohort studies and basic experimentsSemantic proximity Read ↗

New target-HMGCR inhibitors for the treatment of primary sclerosing cholangitis: a drug Mendelian randomization studySemantic proximity Read ↗

Use of Mendelian Randomization to Examine Causal Inference in OsteoporosisSemantic proximity Read ↗

Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.Semantic proximity Read ↗

Application of Mendelian randomization analysis to explore causal associations of aspirin use with bone mineral density and risk of fracture.Semantic proximity Read ↗

Potential Benefits of Statin Therapy in Reducing Osteoarthritis Risk: A Mendelian Randomization Study.Semantic proximity Read ↗

A Mendelian Randomization Study of Cardiovascular Proteins, Immune Cell Traits, and Lifestyle Factors.Semantic proximity Read ↗

Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation.Semantic proximity Read ↗

Comprehensive Mendelian randomization analysis of low-density lipoprotein cholesterol and multiple cancersSemantic proximity Read ↗

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.